CALQUENCE Emerging Drug Insight and Market Forecast - 2032

This “CALQUENCE Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about CALQUENCE for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the CALQUENCE for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the CALQUENCE for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CALQUENCE market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary

CALQUENCE (acalabrutinib) is a next-generation, selective inhibitor of Bruton's tyrosine kinase (BTK). CALQUENCE binds covalently to BTK, thereby inhibiting its activity. In B cells, BTK signaling activates pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.

AstraZeneca and Acerta Pharma are currently evaluating CALQUENCE in more than 20 company-sponsored clinical trials as part of an extensive clinical development program. CALQUENCE is being evaluated for treating multiple B-cell blood cancers, including DLBCL, CLL, MCL, Waldenström's macroglobulinemia, follicular lymphoma, and marginal zone lymphoma (AstraZeneca, 2022b).

AstraZeneca and Acerta Pharma are evaluating CALQUENCE under an extensive clinical development program. The Phase III trial evaluates acalabrutinib in combination with R-CHOP with previously untreated non-germinal center DLBCL (activated B-cell [ABC] and unclassified). The drug in combination with RICE (rituximab, ifosfamide, carboplatin, and etoposide) in the Phase II trial is also evaluated as second-line therapy in relapsed/refractory DLBCL. The combination of acalabrutinib and axicabtagene ciloleucel in Phase I/II is being evaluated as the third line of therapy in treating patients with B-cell lymphoma, including R/R DLBCL.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CALQUENCE description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on CALQUENCE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CALQUENCE research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CALQUENCE.
• The report contains forecasted sales of CALQUENCE for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for CALQUENCE in DLBCL.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publishing team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CALQUENCE Analytical Perspective

In-depth CALQUENCE Market Assessment

This report provides a detailed market assessment of CALQUENCE for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

CALQUENCE Clinical Assessment

The report provides the clinical trials information of CALQUENCE for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CALQUENCE dominance.
• Other emerging products for DLBCL are expected to give tough market competition to CALQUENCE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CALQUENCE in DLBCL.
• Our in-depth analysis of the forecasted sales data of CALQUENCE from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CALQUENCE in DLBCL.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of CALQUENCE?
• What is the clinical trial status of the study related to CALQUENCE in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CALQUENCE development?
• What are the key designations that have been granted to CALQUENCE for DLBCL?
• What is the forecasted market scenario of CALQUENCE for DLBCL?
• What are the forecasted sales of CALQUENCE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to CALQUENCE for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

This product will be delivered within 2 business days.